Analysis of a Study: Emerging Therapies for HoFH

Analysis of a Study: Emerging Therapies for HoFH

Schedule: On Demand (The original live program aired on Tuesday, December 18, 2012)

Program Overview:
This program will analyze results of a recent single-arm, open-label, phase 3 study. Dr. Daniel Rader will discuss microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolemia. This live CME broadcast will provide you the opportunity to address your questions with the expert faculty.

Alan S. Brown, MD, FACC, FAHA, FNLA

President, Midwest Lipid Association
Interventional Cardiologist, Midwest Heart Specialists- Advocate Medical Group
Director, Midwest Heart Disease Prevention Center
Clinical Associate Professor, Loyola University
Maywood, IL

Daniel J. Rader, MD, FNLA

Professor of Medicine
Division Chief of Translational Medicine and
Human Genetics
University of Pennsylvania
Philadelphia, PA

Technical Support

This program requires a current version of ONE of the following web browsers, with JavaScript enabled:

  • Google Chrome
  • Firefox 5.0 or greater
  • Safari
  • Internet Explorer 8.0 or greater

This NLA Lipid Insights Archive Program is Mobile Device friendly. If you experience difficulty viewing the video portion of this program, please contact us.

The handouts portion of this program requires the Adobe Acrobat Reader or a similar PDF program. You probably already have it; but if you cannot view the handouts, you can obtain the Adobe Acrobat Reader here.

If you require assistance to view/hear this program, please contact us.

Average: 4 (1 vote)

Education Information

This program, though not accredited in its archived form, is targeted towards specific content areas and learning objectives.

Content Domain
This activity falls under the following content domain(s):

  • 3.1.1 Familial hypercholesterolemia (FH) and other autosomal dominant hypercholesterolemias

Learning Objectives
This activity teaches to the following learning objective(s):

  1. Evaluate the clinical effects, safety and efficacy data for current and new treatment options for FH patients.
  2. Improve the diagnosis and treatment of patients with homozygous and heterozygous FH